If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The company does not expect the outcome of this inspection to impact its plans
It is a recombinant nanoparticle protein-based vaccine
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
Subscribe To Our Newsletter & Stay Updated
